Mandate Vinge has advised Aprea Therapeutics in connection with its EUR 50 million financing

December 04, 2018

Aprea Therapeutics AB, with headquarters in Stockholm (Solna), is a biotechnology company focused on the discovery and development of new cancer drugs reactivating the tumour suppressor protein p53. 

Vinge has advised Aprea Therapeutics in connection with its EUR 50 million series C financing round, led by the Redmile Group and with participation by the new investor Rock Springs Capital and the existing shareholders 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management, Karolinska Development AB.

Vinge’s team consisted of Kristina Ekberg, Peter Issa and Tove Lövgren Frisk. 

M&A in Sweden and the impact of COVID-19

We started to see signs of a decrease in M&A activity during Q4 2019 and following a relatively sluggish start to 2020, COVID-19 has had a significant impact on M&A activity in Sweden. In this note we address some of the key observations.
April 07, 2020

Update regarding the implications of Covid-19 for upcoming AGMs

The outbreak of the coronavirus disease has had a significant impact on people and businesses. The situation has also raised questions about the possibility of physical attendance at upcoming AGMs. Due to new temporary legislation and new instructions regarding the interpretation of the Swedish Corporate Governance Code, as well as the authorities’ updated recommendations, Vinge publishes this update regarding companies' alternatives for the upcoming AGMs.
April 03, 2020

Brexit and data protection

The transfer of personal data is of key importance to many businesses. It is an area that is affected by Brexit and companies must consider how to deal with the changes brought upon by the British departure. This note discusses the implications of Brexit for the transfer of personal data and offers guidance to companies and other parties.
April 01, 2020